Separate the needle from the haystack

Current sequencing methods, designed to sequence the whole genome, are simply over-dimensioned for the task of prenatal screening. Even in targeted sequencing, unnecessarily large volumes of genetic data that are irrelevant for aneuoploidy screening must be sequenced and counted. Vanadis™ NIPT converts only the targeted chromosome regions to fluorescent DNA objects, which are then directly quantified on a microtiter plate scanner.


Vanadis NIPT technology
nipt_tech
cfDNA is extracted
from maternal
plasma.

Thousands of targeted cfDNA fragments are captured and converted to DNA circles.

Rolling circle amplification products are labeled with chromosome specific fluorophores.
The labeled objects are individually counted using a microtiter plate based scanner.

Vanadis™ NIPT is under development. The system does notconform to 98/79 EC In Vitro Diagnostic Medical device directive and cannot beplaced on the market or put into service in EU until they have been made tocomply.

Say goodbye to big data

Unlike the DNA sequencing methods of other NIPT platforms, Vanadis™ NIPT is designed to achieve the same results without using complex genetic data. Its ability to count only the right chromosome targets with very high precision and specificity means that the vast majority of irrelevant chromosomal data no longer needs to be generated.


Train staff in days, not months

Laboratory staff will be able to be trained to operate the Vanadis system in a matter of days, rather than the months of specialized training associated with comparable sequencing-based platforms. Individual samples and reagents are tracked with barcode scanners. And the entire automated process – from primary blood tube to result – will be completed in just 3-4 days. This substantially simplified testing process will make Vanadis NIPT ideally suited to low-complexity laboratory environments.


Vanadis™ NIPT is under development. The system does notconform to 98/79 EC In Vitro Diagnostic Medical device directive and cannot beplaced on the market or put into service in EU until they have been made tocomply.



Follow us to learn more

The Vanadis NIPT has gone through investigational studies during development with positive results. To receive updates on current clinical studies, an upcoming clinical white paper or to learn more about product release dates in your region, register here.


Vanadis™ NIPT is under development. The system does notconform to 98/79 EC In Vitro Diagnostic Medical device directive and cannot beplaced on the market or put into service in EU until they have been made tocomply.